Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRPa…
Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage biotech company announced that Boehringer will be progressing their first-in-class SIRPα immuno-oncology…
Read More...
Read More...
